Solved Case Analysis: Abiomed and the AbioCor Clinical Trials B by Elizabeth A. Powell, Rebecca Goldberg

0.00$

Get the Best Analysis to this Case Study written by MBA/CFA writers.

**Solution would be delivered to your registered email address within next 4 days. If you want the solution any earlier drop an email at assignment@writerkingdom.com.  Click Here to see how it works

Compare

Description

In late 2002, a sensational article in the New York Times depicting James Quinn’s experience and death following implantation with the AbioCor artificial heart raises questions about Abiomed’s handling of the informed consent process related to its clinical trials. At the same time, investor confidence in the company wanes due to the apparent stall in the clinical trial’s progress. This B case illustrates Abiomed’s handling of the situation, along with commentary from onlookers including those close to Quinn’s case, as well as medical ethicists and financial investors and analysts. An analysis of Abiomed’s choices reveals the company’s apparent strategy as one of downplaying the significance of the Times article and reinforcing its message to investors to protect the company’s falling stock price. The B case also reveals how the company changed the 30-day “quiet period” that had become a lightning rod in the media.

Publishing Authority:

Darden Business Publishing – University of Virginia

Reviews

There are no reviews yet.

Be the first to review “Solved Case Analysis: Abiomed and the AbioCor Clinical Trials B by Elizabeth A. Powell, Rebecca Goldberg”

Your email address will not be published. Required fields are marked *